JP2024510504A - 血漿カリクレインの多環式インヒビター - Google Patents

血漿カリクレインの多環式インヒビター Download PDF

Info

Publication number
JP2024510504A
JP2024510504A JP2023557370A JP2023557370A JP2024510504A JP 2024510504 A JP2024510504 A JP 2024510504A JP 2023557370 A JP2023557370 A JP 2023557370A JP 2023557370 A JP2023557370 A JP 2023557370A JP 2024510504 A JP2024510504 A JP 2024510504A
Authority
JP
Japan
Prior art keywords
cyclopropyl
mmol
methyl
independently selected
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023557370A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022197789A5 (https=
JP2024510504A5 (https=
Inventor
パパイオアンヌー，ニコラス
マーク トラヴィンス，ジェレミー
ジョセリン フィンク，サラ
マーク エラード，ジョン
レイ，アラステア
シェーン ランキン，スチュアート
スチュアート ローリー チャップマン，ロバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2024510504A publication Critical patent/JP2024510504A/ja
Publication of JPWO2022197789A5 publication Critical patent/JPWO2022197789A5/ja
Publication of JP2024510504A5 publication Critical patent/JP2024510504A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023557370A 2021-03-17 2022-03-16 血漿カリクレインの多環式インヒビター Pending JP2024510504A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162483P 2021-03-17 2021-03-17
US63/162,483 2021-03-17
PCT/US2022/020527 WO2022197789A1 (en) 2021-03-17 2022-03-16 Polycyclic inhibitors of plasma kallikrein

Publications (3)

Publication Number Publication Date
JP2024510504A true JP2024510504A (ja) 2024-03-07
JPWO2022197789A5 JPWO2022197789A5 (https=) 2025-03-25
JP2024510504A5 JP2024510504A5 (https=) 2025-03-25

Family

ID=81328648

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557370A Pending JP2024510504A (ja) 2021-03-17 2022-03-16 血漿カリクレインの多環式インヒビター

Country Status (5)

Country Link
US (1) US20240199613A1 (https=)
EP (1) EP4308564A1 (https=)
JP (1) JP2024510504A (https=)
CN (1) CN117355523A (https=)
WO (1) WO2022197789A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200143376A (ko) 2018-03-13 2020-12-23 샤이어 휴먼 지네틱 테라피즈 인크. 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도
CN114667289B (zh) 2019-09-18 2025-08-26 武田药品工业有限公司 杂芳基血浆激肽释放酶抑制剂
EP4031547B1 (en) 2019-09-18 2024-07-17 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof
CN118239959A (zh) * 2022-12-23 2024-06-25 上海深势唯思科技有限责任公司 环丙烷类tlr7和8抑制剂及其制备方法和用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004518743A (ja) * 2000-12-21 2004-06-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
JP2008501707A (ja) * 2004-06-04 2008-01-24 アイコス、コーポレーション マスト細胞障害を処置するための方法
JP2009518296A (ja) * 2005-11-30 2009-05-07 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−Ｍｅｔ阻害剤及び用法
CN104059069A (zh) * 2013-08-22 2014-09-24 程刚 一种替卡格雷的制备方法
JP2015526410A (ja) * 2012-06-26 2015-09-10 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
WO2015164308A1 (en) * 2014-04-22 2015-10-29 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
WO2019178129A1 (en) * 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO2013052526A1 (en) * 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. Triazolyl pde10 inhibitors

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004518743A (ja) * 2000-12-21 2004-06-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
JP2008501707A (ja) * 2004-06-04 2008-01-24 アイコス、コーポレーション マスト細胞障害を処置するための方法
JP2009518296A (ja) * 2005-11-30 2009-05-07 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−Ｍｅｔ阻害剤及び用法
JP2015526410A (ja) * 2012-06-26 2015-09-10 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
CN104059069A (zh) * 2013-08-22 2014-09-24 程刚 一种替卡格雷的制备方法
WO2015164308A1 (en) * 2014-04-22 2015-10-29 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
WO2019178129A1 (en) * 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
REGISTRY (STN) [ONLINE], JPN7025005273, ISSN: 0005749323 *
REGISTRY (STN) [ONLINE], JPN7025005274, ISSN: 0005749322 *

Also Published As

Publication number Publication date
EP4308564A1 (en) 2024-01-24
CN117355523A (zh) 2024-01-05
US20240199613A1 (en) 2024-06-20
WO2022197789A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
US11780837B2 (en) CXCR4 inhibitors and uses thereof
JP7777519B2 (ja) 血漿カリクレインインヒビター及びその使用
JP7376218B2 (ja) Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法
JP7590183B2 (ja) 血漿カリクレインのインヒビターとしての置換されたイミダゾピリジン及びその使用
JP7082130B2 (ja) Ｔｙｋ２阻害剤およびその使用
RU2720237C2 (ru) Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
JP2024510504A (ja) 血漿カリクレインの多環式インヒビター
IL311024A (en) Substituted tricyclic compounds as parp inhibitors and use thereof
TW201900612A (zh) 吲哚甲醯胺化合物
WO2022037630A1 (zh) 四环类衍生物、其制备方法及其医药上的用途
IL301501B1 (en) Antiproliferation compounds and uses thereof
CN117396469A (zh) 血浆激肽释放酶的抑制剂
TW202519211A (zh) 經取代之胺基吡啶化合物及用其治療疾病之方法
JP2024510502A (ja) 血漿カリクレインのイミダゾピリジニル阻害剤
TW202530222A (zh) 異雙官能化合物及治療疾病之方法
US20260092057A1 (en) Bcl-xl/bcl-2 degraders and uses thereof
WO2023169170A1 (zh) 作为shp2抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法
WO2024264070A2 (en) Akt inhibitors
HK40091563B (zh) 嘧啶酮类化合物及其用途
HK40091563A (zh) 嘧啶酮类化合物及其用途
HK40074859B (en) Plasma kallikrein inhibitors and uses thereof
HK40074859A (en) Plasma kallikrein inhibitors and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250314

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260406